Related references
Note: Only part of the references are listed.Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply
Erin F. Cobain et al.
JAMA ONCOLOGY (2021)
Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?
Giancarlo Pruneri et al.
PHARMACOECONOMICS-OPEN (2021)
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
Aditi P. Singh et al.
CANCERS (2020)
When should we order a next generation sequencing test in a patient with cancer?
Ramon Colomer et al.
ECLINICALMEDICINE (2020)
Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials
Ida Viller Tuxen et al.
CLINICAL CANCER RESEARCH (2019)
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J. Mateo et al.
ANNALS OF ONCOLOGY (2018)
Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the ProfiLER study
Olivier Tredan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy
Talal Hilal et al.
BMC CANCER (2017)
Implementing Genome-Driven Oncology
David M. Hyman et al.
CELL (2017)
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
Jennifer J. Wheler et al.
CANCER RESEARCH (2016)
Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers
Kim M. Hirshfield et al.
ONCOLOGIST (2016)
Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers
Milan Radovich et al.
ONCOTARGET (2016)
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau et al.
LANCET ONCOLOGY (2015)
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response
Himisha Beltran et al.
JAMA ONCOLOGY (2015)
Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel
Douglas B. Johnson et al.
ONCOLOGIST (2014)
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Apostolia-Maria Tsimberidou et al.
CLINICAL CANCER RESEARCH (2012)
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Share Paper
